HealthQuill Alzheimer's Disease
Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study finds.
Drugs Health Pharma

Diet, exercise, socialisation may help in early stage Alzheimer’s disease

Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study.

Read More
The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus on medicines that are likely to predict a clinical benefit.
Drugs Health Pharma

FDA issues revised drug guidelines for early Alzheimer’s disease

HQ Team March 12, 2024: The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus.

Read More
Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous treatments.
Drugs Health Pharma

Researchers find five cases of medically-acquired Alzheimer’s in UK

HQ Team February 12, 2024: Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous.

Read More
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More
AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.
Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

Read More
Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a global study.
Drugs Health Pharma

Scientists connect gut microbiota to Alzheimer’s disease in lab experiments

HQ Team October 19, 2023: Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a.

Read More
Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops symptoms.
Drugs Health Pharma

Swedish researchers identify new biomarker to detect Parkinson’s disease

HQ Team September 26, 2023: Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops.

Read More
Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for detecting Alzheimer’s disease early.
Drugs Health Pharma

Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s 

HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.

Read More
Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.
Drugs Health Pharma

Eli Lilly: Alzheimer’s test drug slows cognitive decline in early stages

HQ Team July 18, 2023: Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of.

Read More
The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.
Drugs Health Pharma

USFDA grants green light to Eisai, Biogen’s Alzheimer’s drug Leqembi

HQ Team July 7, 2023: The USFDA has granted a standard approval for Eisai and Biogen’s Alzheimer injection, Leqembi —the first treatment to secure the.

Read More
X